Twist Bioscience Corp. (TWST)

In the past six months, Twist Bioscience's stock price has increased by 93.86% due to its financial performance and outlook. In Q1 2026, the company reported revenue of $103.7 million, surpassing forecasts by 2.96% and marking a 17% year-over-year growth, but missed EPS estimates. Following the Q1 results, the company raised its full-year 2026 sales outlook to a range of $435 million to $440 million and reiterated its ambition to achieve adjusted EBITDA breakeven by Q4 fiscal year 2026. The stronger Q1 update and raised outlook contributed to a sharp shift in sentiment, with the stock experiencing positive returns.

There is no explicit information indicating significant demand seasonality for Twist Bioscience's products and services. The company has demonstrated consistent year-over-year revenue growth across its various segments. The increasing demand from AI-enabled drug discovery customers is highlighted as a major growth driver, suggesting a continuous and expanding market rather than seasonal fluctuations.

Twist Bioscience Corp. is a synthetic biology company operating in the Pharmaceuticals and Healthcare sector, specifically in the Biotechnology industry. Its products serve diverse applications such as cancer research, DNA data storage, drug discovery, and infectious diseases, catering to the healthcare, industrial chemicals, agriculture, and academic research sectors. Major products include synthetic genes, oligo pools, next-generation sequencing products, variant libraries, synthetic controls products, antibody discovery products and services, IVDR compliant products, and plasmid DNA preps.

Twist Bioscience has a global geographic footprint, operating across the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific) regions. The Americas segment includes the United States, Canada, Mexico, and South America. The EMEA segment covers Europe, the Middle East, and Africa, while the APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The majority of the company's revenue is derived from the Americas.

Twist Bioscience's brand reputation has been shaped by its innovation, strategic moves, and financial performance. The company is recognized for its innovative DNA synthesis platform and its ability to define new categories. Twist Bioscience spun off its DNA data storage application into an independent company, Atlas Data Storage, securing $155 million in funding. The introduction of research-grade Plasmid DNA Preps for therapeutics R&D demonstrates the company's commitment to product innovation. Recent analyst ratings show a mix of bullish sentiments. In November 2022, Scorpion Capital alleged that Twist Bioscience was overstating the commercial viability of its synthetic DNA manufacturing technology and engaging in accounting fraud, which the company has denied.

Twist Bioscience Corporation has a significant number of institutional owners and shareholders, with 491 institutional owners holding a total of 92,361,874 shares. Major institutional owners include ARK Investment Management LLC, Artisan Partners Limited Partnership, BlackRock, Inc., Vanguard Group Inc, William Blair Investment Management, LLC, EdgePoint Investment Group Inc., State Street Corp, Nikko Asset Management Americas, Inc., ARK Innovation ETF (ARKK), and ARK Genomic Revolution ETF (ARKG). The company was co-founded by Emily Leproust, Bill Banyai, and Bill Peck in 2013, who are considered significant individual owners.